Shifting Supply Chain To Asia Will Require More Quality Control Vigilance - World Pharma Manufacturing Summit
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - As Big Pharma continues to shift API manufacturing and contract manufacturing to Asia, it must be vigilant in verifying quality even as regulatory agencies in the region enact more stringent guidelines, according to speakers at the World Pharma Manufacturing Summit in Shanghai
You may also be interested in...ï»¿
Transitioning Public Health To Non-communicable Diseases In Emerging Markets Highlights Supply Chain Gaps
When looking for ways to care for chronic diabetes and hypertension patients, Cambodia looked to its experiences dealing with HIV/AIDS.